Rockwell Medical, Inc.

RMTI

US7743743004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
1.8 ^USD	+1.98%		+5.88%	-4.76%

May. 14	Transcript : Rockwell Medical, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 14	Earnings Flash (RMTI) ROCKWELL MEDICAL Reports Q1 Revenue $22.7M, vs. Street Est of $21.7M	MT

Rockwell Medical, Inc. Provides Financial Guidance for the Third Quarter of 2023

August 14, 2023 at 06:00 am EDT

Rockwell Medical, Inc. provided financial guidance for the third quarter of 2023. The company anticipates that third quarter 2023 net sales will be between $21.0 million and $23.0 million.

Latest news about Rockwell Medical, Inc.

Transcript : Rockwell Medical, Inc., Q1 2024 Earnings Call, May 14, 2024	May. 14
Earnings Flash (RMTI) ROCKWELL MEDICAL Reports Q1 Revenue $22.7M, vs. Street Est of $21.7M	May. 14	MT
Rockwell Medical, Inc. Provides Earnings Guidance for the Year 2025	May. 14	CI
Rockwell Medical, Inc. Revises Earnings Guidance for the Year 2024	May. 14	CI
Rockwell Medical Continues to Expand Its Distribution Capabilities in Western United States	Apr. 17	CI
Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda	Apr. 04	CI
HC Wainwright Cuts Price Target on Rockwell Medical to $9 From $11, Keeps Buy Rating	Mar. 25	MT
Transcript : Rockwell Medical, Inc., Q4 2023 Earnings Call, Mar 21, 2024	Mar. 21
(RMTI) ROCKWELL MEDICAL Expects Fiscal Year 2024 Revenue Range $84M - $88M	Mar. 21	MT
Earnings Flash (RMTI) ROCKWELL MEDICAL Posts Q4 Revenue $22.1M	Mar. 21	MT
Rockwell Medical, Inc. Provides Earnings Guidance for the Year 2024	Mar. 21	CI
Rockwell Medical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Earnings Flash (RMTI) ROCKWELL MEDICAL Reports Q4 EPS $0.02	Mar. 21	MT
Rockwell Medical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Rockwell Medical, Inc. Provides Earnings Guidance for Fourth Quarter and Full-Year 2023	Jan. 08	CI
Rockwell Medical Amends Loan and Security Agreement with Innovatus Life Sciences Lending Fund	Jan. 08	CI
Transcript : Rockwell Medical, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Earnings Flash (RMTI) ROCKWELL MEDICAL Reports Q3 Revenue $23.8M	Nov. 14	MT
Rockwell Medical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Rockwell Medical, Inc. Provides Financial Guidance for the Year 2023	Nov. 14	CI
Rockwell Medical, Inc. Appoints Jesse Neri as Senior Vice President, Finance	23-10-18	CI
Rockwell Medical, Inc. Appoints Joan Lau, Ph.D. to the Company's Board of Directors	23-10-17	CI
Maxim Initiates Coverage on Rockwell Medical with Buy Rating, $5 Price Target	23-10-05	MT
Rockwell Medical to be the Preferred Supplier of Hemodialysis Concentrates, Accessories to Centers for Dialysis Care	23-10-03	MT
Rockwell Medical Signs Multi-Year Product Purchase Deal With Centers for Dialysis Care; Shares Climb Premarket	23-10-03	MT

Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers around the world. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. It is the supplier of life-sustaining hemodialysis concentrates products to dialysis clinics. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patientâs bloodstream. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.

Sector

Pharmaceuticals

Calendar

10:00am - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Rockwell Medical, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.8 USD

Average target price

7 USD

Spread / Average Target

+288.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCKWELL MEDICAL, INC.	-4.76%	52.86M
ELI LILLY AND COMPANY	+34.35%	705B
NOVO NORDISK A/S	+31.01%	583B
JOHNSON & JOHNSON	-3.49%	364B
MERCK & CO., INC.	+20.15%	332B
ABBVIE INC.	+6.19%	291B
ASTRAZENECA PLC	+15.11%	238B
ROCHE HOLDING AG	-3.44%	210B
NOVARTIS AG	+10.06%	209B
AMGEN INC.	+9.21%	169B

Other Pharmaceuticals